These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 32197529)

  • 41. Mismatch repair deficiency in Lynch syndrome-associated colorectal adenomas is more prevalent in older patients.
    Tanaka M; Nakajima T; Sugano K; Yoshida T; Taniguchi H; Kanemitsu Y; Nagino M; Sekine S
    Histopathology; 2016 Aug; 69(2):322-8. PubMed ID: 26826556
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutation-specific Mismatch Repair-deficient Benign Endometrial Glands in Endometrial Biopsies and Curettings Are a Biomarker of Lynch Syndrome and Associate With Endometrial Carcinoma Development.
    Hegazy S; Brand RE; Dudley B; Karloski E; Lesnock JL; Elishaev E; Pai RK
    Am J Surg Pathol; 2023 Jul; 47(7):835-843. PubMed ID: 37226842
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Germline Mutations in MLH1 Leading to Isolated Loss of PMS2 Expression in Lynch Syndrome: Implications for Diagnostics in the Clinic.
    Silva FCC; Torrezan GT; Ferreira JRO; Oliveira LP; Begnami MDFS; Aguiar S; Carraro DM
    Am J Surg Pathol; 2017 Jun; 41(6):861-864. PubMed ID: 28248820
    [No Abstract]   [Full Text] [Related]  

  • 44. PMS2 involvement in patients suspected of Lynch syndrome.
    Niessen RC; Kleibeuker JH; Westers H; Jager PO; Rozeveld D; Bos KK; Boersma-van Ek W; Hollema H; Sijmons RH; Hofstra RM
    Genes Chromosomes Cancer; 2009 Apr; 48(4):322-9. PubMed ID: 19132747
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence of CNV-neutral structural genomic rearrangements in MLH1, MSH2, and PMS2 not detectable in routine NGS diagnostics.
    Morak M; Steinke-Lange V; Massdorf T; Benet-Pages A; Locher M; Laner A; Kayser K; Aretz S; Holinski-Feder E
    Fam Cancer; 2020 Apr; 19(2):161-167. PubMed ID: 32002723
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation.
    Kaya M; Post CCB; Tops CM; Nielsen M; Crosbie EJ; Leary A; Mileshkin LR; Han K; Bessette P; de Boer SM; Jürgenliemk-Schulz IM; Lutgens L; Jobsen JJ; Haverkort MAD; Nout RA; Kroep J; Creutzberg CL; Smit VTHBM; Horeweg N; van Wezel T; Bosse T
    Mod Pathol; 2024 Mar; 37(3):100423. PubMed ID: 38191122
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
    Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
    J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gene-Specific Variation in Colorectal Cancer Surveillance Strategies for Lynch Syndrome.
    Kastrinos F; Ingram MA; Silver ER; Oh A; Laszkowska M; Rustgi AK; Hur C
    Gastroenterology; 2021 Aug; 161(2):453-462.e15. PubMed ID: 33839100
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers].
    Hu XR; Xu C; Kang Y; Wang T; Zhang Y; Yang XH
    Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):827-833. PubMed ID: 30423605
    [No Abstract]   [Full Text] [Related]  

  • 50. Pseudomyxoma peritonei of a mature ovarian teratoma caused by mismatch repair deficiency in a patient with Lynch syndrome: a case report.
    Gohda Y; Noguchi R; Horie T; Igari T; Nakamura H; Ohta Y; Yamaguchi K; Ikenoue T; Hatakeyama S; Yusa N; Furukawa Y; Yano H
    BMC Med Genet; 2016 Dec; 17(1):94. PubMed ID: 27938333
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unique
    Serra S; Capo-Chichi JM; McCarthy AJ; Sabatini P; Chetty R
    J Clin Pathol; 2020 May; 73(5):291-295. PubMed ID: 31649038
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Microsatellite Instability in Endometrial Carcinoma by Immunohistochemistry, Association with Clinical and Histopathologic Parameters.
    Hashmi AA; Mudassir G; Hashmi RN; Irfan M; Asif H; Khan EY; Abu Bakar SM; Faridi N
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2601-2606. PubMed ID: 31554352
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MLH1 Promotor Hypermethylation in Colorectal and Endometrial Carcinomas from Patients with Lynch Syndrome.
    Helderman NC; Andini KD; van Leerdam ME; van Hest LP; Hoekman DR; Ahadova A; Bajwa-Ten Broeke SW; Bosse T; van der Logt EMJ; Imhann F; Kloor M; Langers AMJ; Smit VTHBM; Terlouw D; van Wezel T; Morreau H; Nielsen M
    J Mol Diagn; 2024 Feb; 26(2):106-114. PubMed ID: 38061582
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The added value of PMS2 immunostaining in the diagnosis of hereditary nonpolyposis colorectal cancer.
    Halvarsson B; Lindblom A; Rambech E; Lagerstedt K; Nilbert M
    Fam Cancer; 2006; 5(4):353-8. PubMed ID: 16817031
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of novel pathogenic MSH2 mutation and new DNA repair genes variants: investigation of a Tunisian Lynch syndrome family with discordant twins.
    Jaballah-Gabteni A; Tounsi H; Kabbage M; Hamdi Y; Elouej S; Ben Ayed I; Medhioub M; Mahmoudi M; Dallali H; Yaiche H; Ben Jemii N; Maaloul A; Mezghani N; Abdelhak S; Hamzaoui L; Azzouz M; Boubaker S
    J Transl Med; 2019 Jun; 17(1):212. PubMed ID: 31248416
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?
    Marabelli M; Gandini S; Rafaniello PR; Calvello M; Tolva G; Feroce I; Lazzeroni M; Marino E; Dal Molin M; Trovato C; Guerrieri-Gonzaga A; Petz WL; Barberis M; Bertario L; Bonanni B
    Dig Liver Dis; 2020 Dec; 52(12):1503-1511. PubMed ID: 32620519
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer.
    Malander S; Rambech E; Kristoffersson U; Halvarsson B; Ridderheim M; Borg A; Nilbert M
    Gynecol Oncol; 2006 May; 101(2):238-43. PubMed ID: 16360201
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mismatch repair deficiency testing in clinical practice.
    Buza N; Ziai J; Hui P
    Expert Rev Mol Diagn; 2016; 16(5):591-604. PubMed ID: 26895074
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
    Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
    Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nine novel pathogenic germline mutations in MLH1, MSH2, MSH6 and PMS2 in families with Lynch syndrome.
    Rahner N; Friedrichs N; Wehner M; Steinke V; Aretz S; Friedl W; Buettner R; Mangold E; Propping P; Walldorf C
    Acta Oncol; 2007; 46(6):763-9. PubMed ID: 17653898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.